抗帕金森精神病新药Nuplazid上市后临床研究进展
Progress in post-marketing clinical researches for Nuplazid
陈佩琪 1周微 2王晓毅2
作者信息
- 1. 丹东市药品检验检测中心,辽宁丹东 118000
- 2. 天士力医药集团股份有限公司,天津 300410
- 折叠
摘要
帕金森病精神病(Parkinson's disease psychosis,PDP)是帕金森病中一种常见的非运动性特征性疾病.在Nuplazid上市之前,临床上并无针对性药物用于治疗PDP.Nuplazid的作用机制为通过五羟色胺(5-HT)2A受体的反向激动剂和拮抗剂活性的结合调节,从而治疗PDP.目前国内已有学者系统整理了该药物上市前的药学和临床资料,但并未对上市后的临床研究进行整理.该文旨在系统整理Nuplazid上市后的临床情况,并对相关问题进行讨论,给出引进或仿制该药品的相关建议.
Abstract
Parkinson's disease psychosis(PDP)is a common non-motor manifestation of Parkinson's disease.Before the mar-keting of Nuplazid,no drug is readily available for treating PDP in clinical practices.Its mechanism of action lies in regulating the binding activity of reverse agonists and antagonists of serotonin 5-HT2A receptor.Domestic scholars have systematically com-piled the pharmaceutical and clinical data of this drug before its launch.However,there is a lack of clinical researches after its launch.This review summarized the latest studies of Nuplazid after its launch.The relevant issues were discussed to offer reason-able suggestions for introducing or replicating its analogues.
关键词
帕金森病精神病/匹莫范色林/上市后临床研究Key words
Parkinson's disease psychosis/pimavanserin/post-marketing clinical studies引用本文复制引用
出版年
2024
NETL
NSTL
万方数据